Cusatuzumab is under clinical development by OncoVerity and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase II drugs for Myelodysplastic Syndrome have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Cusatuzumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cusatuzumab (ARGX-110) is under development for the treatment of solid tumors, such as renal cell carcinoma, acute promyelocytic leukemia, platinum-refractory ovarian cancer, head and neck cancer, nasopharyngeal carcinoma, myoepithelial carcinoma, mesothelioma and hematological malignancies including refractory Waldenstrom’s macroglobulinemia (WM), relapsed/refractory T-cell lymphomas such as Sezary syndrome (cutaneous T-cell lymphoma), angioimmunoblastic T-cell lymphoma (AITL), acute myeloid leukemia(AML) and high risk myelodysplatic syndrome. The therapeutic candidate is administered through intravenous or subcutaneous route. It is a glyco-engineered fully human antibody developed based on SIMPLE antibody platform. ARGX-110 is equipped with Potelligent to enhance its ability to destroy CD70-positive tumor cells.
The drug candidate was also under development for chronic myelocytic leukemia (CML), inflammatory and autoimmune disorders, epithelial tumor, chronic myelomonocytic leukemia (CMML).
For a complete picture of Cusatuzumab’s drug-specific PTSR and LoA scores, buy the report here.